IMF Videos Search Content For Healthcare Professional (182) Healthcare Provider (182) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (247) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Carfilzomib Twice Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and Dex December 11, 2020 ASH Outcomes from the CARTITUDE-1 Study Assessing CAR T-Cell Therapy in Relapsed Refractory Multiple Myeloma December 10, 2020 ASH TOURMALINE-MM2: Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM December 10, 2020 ASH Non-invasive monitoring of smoldering multiple myeloma: The iMMunocell study December 9, 2020 ASH Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients December 9, 2020 ASH A Phase 1 Study of AMG 701 in Subjects With Relapsed/Refractory Multiple Myeloma December 8, 2020 ASH Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients Enrolled in the Forte Trial December 8, 2020 ASH Updated Efficacy and Safety Results of the Phase 3 CANDOR study December 8, 2020 ASH Accelerating Toward Curing Myeloma: New Data, New Agents, and Evolving Treatment Paradigm December 4, 2020 ASH Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dex in Unfit and Frail NDMM Patients January 5, 2020 ASH Dara-VMP prolonga la SG en pacientes con pacientes con mieloma múltiple recién diagnosticados no elegibles para trasplante December 15, 2019 ASH Dara-VMP prolongs OS in patients with transplant-ineligible Newly Diagnosed Multiple Myeloma Patients December 15, 2019 ASH Load More
